Huh?
Busy guy...
Geneva, Switzerland, 9 March 2011 - Allosteric modulation company Addex
Pharmaceuticals (swiss:ADXN) announced today that the Board of Directors proposes
to the Annual General Meeting of 28 April 2011 that Dr. Hoyoung Huh and Mr. Oleg
Nodelman be elected to the Board of Directors of Addex Pharmaceuticals Ltd.
Hoyoung Huh, 41, U.S. citizen, is Chairman of the Boards of BiPar Sciences Inc.,
Geron Corp. (GERN), and Epizyme Inc. He is a global leader in the biotechnology
and healthcare arena, being9 involved in formation and growth of innovative
organizations across the U.S., Europe and Asia. Dr. Huh was BiPar's President and
CEO, where he led the merger of BiPar with the French pharmaceutical firm
Sanofi-Aventis in 2009. BiPar is now an independent, wholly owned subsidiary and
center of innovation within the Sanofi-Aventis Group. He also serves on the Board
of Directors at BayBio, Jennerex, SciDose, and on the Presidential Advisory
Council of the Berklee College of Music. He was previously a member of the Board
of Directors, Chief Operating Officer, and Head of the PEGylation Business Unit
at Nektar Therapeutics (NKTR). Dr. Huh was formerly a Partner at McKinsey and
Company. Dr. Huh holds an M.D. from Cornell University Medical College, a Ph.D.
in Genetics/Cell Biology from Cornell University/Sloan-Kettering Institute, and a
bachelor's degree in biochemistry from Dartmouth College.
Oleg Nodelman, 34, U.S. citizen, is a Portfolio Manager at the Biotechnology
Value Fund, a biotech focused investment fund founded in San Francisco in 1993.
Before joining BVF, Mr. Nodelman was a consultant with Mercer Management
Consulting where he worked closely with senior management on financial and
strategic matters. Mr. Nodelman holds a Bachelor of Science in International
Affairs and a minor in Science in Technology from the School of Foreign Service
at Georgetown University. BVF is a 15.15% shareholder of Addex and on 14 March
following conversion of outstanding notes will hold 30% of Addex. |
